Issue navigation
Volume 112, Issue 9, September 2020
Editorials
Data Sharing for the Public Good
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 9, September 2020, Pages 867–868, https://doi.org/10.1093/jnci/djz242
The Evolving Status of Radiomics
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 9, September 2020, Pages 869–870, https://doi.org/10.1093/jnci/djaa018
Why Y? Downregulation of Chromosome Y Genes Potentially Contributes to Elevated Cancer Risk
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 9, September 2020, Pages 871–872, https://doi.org/10.1093/jnci/djz236
Staging for Melanoma - Toward a New Paradigm?
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 9, September 2020, Pages 873–874, https://doi.org/10.1093/jnci/djaa009
Commentary
Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 9, September 2020, Pages 875–885, https://doi.org/10.1093/jnci/djaa012
Review
Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 9, September 2020, Pages 886–892, https://doi.org/10.1093/jnci/djaa044
Articles
Genetic Factors, Adherence to Healthy Lifestyle Behavior, and Risk of Invasive Breast Cancer Among Women in the UK Biobank
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 9, September 2020, Pages 893–901, https://doi.org/10.1093/jnci/djz241
Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 9, September 2020, Pages 902–912, https://doi.org/10.1093/jnci/djaa017
Extreme Downregulation of Chromosome Y and Cancer Risk in Men
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 9, September 2020, Pages 913–920, https://doi.org/10.1093/jnci/djz232
Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 9, September 2020, Pages 921–928, https://doi.org/10.1093/jnci/djaa008
Sustained Weight Loss and Risk of Breast Cancer in Women 50 Years and Older: A Pooled Analysis of Prospective Data
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 9, September 2020, Pages 929–937, https://doi.org/10.1093/jnci/djz226
Emergency Department Visits for Opioid Overdoses Among Patients With Cancer
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 9, September 2020, Pages 938–943, https://doi.org/10.1093/jnci/djz233
HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 9, September 2020, Pages 944–954, https://doi.org/10.1093/jnci/djz231
Estimating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative Analysis
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 9, September 2020, Pages 955–963, https://doi.org/10.1093/jnci/djz227
Brief Communication
Antihistamines and Ovarian Cancer Survival: Nationwide Cohort Study and in Vitro Cell Viability Assay
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 9, September 2020, Pages 964–967, https://doi.org/10.1093/jnci/djz217
Correspondence
RE: Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 9, September 2020, Pages 968–969, https://doi.org/10.1093/jnci/djaa074
Response to Brandt, Bednarz-Knoll, Kleinheinz et al
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 9, September 2020, Pages 970–971, https://doi.org/10.1093/jnci/djaa075
Reviewers
Reviewers
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 9, September 2020, Pages 972–974, https://doi.org/10.1093/jnci/djaa123
